NuCana plc(NCNA)Earnings, Financials & Key Ratios
NCNA•NASDAQ
$1.58
Price updated Jun 30, 2026
AboutNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Show more
- Revenue$0
- EBITDA-$20M+11.0%
- Net Income-$29M-54.5%
- EPS (Diluted)-7.75-137.0%
- ROE-193.87%-6.3%
NCNA Price & Volume
NuCana plc (NCNA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Volatility Strains Capital Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Limited clinical cash runway
Key Thesis Takeaways
- NuCana remains a high-risk, clinical-stage biotechnology firm currently navigating a precarious financial transition following the discontinuation of its Acelarin program.
- The company's reliance on R&D-heavy spending, which reached $7.1 million in 2025Q2, continues to erode equity, with retained earnings now standing at negative $251.2 million.
- Investors should monitor the firm's ability to manage its $21.5 million cash position against ongoing operational losses, as the lack of commercial revenue streams necessitates potential dilutive financing to sustain future research milestones.
Verdict Logic
the company's precarious liquidity profile, highlighted by a rapid depletion of cash reserves to $21.5 million in 2026Q1, suggests significant ongoing risk for shareholders.
NCNA Growth Metrics
NuCana plc (NCNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-110.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM94.34%
Return on Capital
10 Years-77.35%
5 Years-120.68%
3 Years-155.04%
Last Year-129.12%
Peers Comparison
Key metrics vs top competitors for NuCana plc (NCNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.58 | $9.59M | -0.15 | — | — | -193.87% | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — | |
| $38.51 | $7.91B | -13.90 | — | — | -68.16% | — | |
| $55.72 | $8.53B | 20.12 | 87.32% | 65.95% | 87.36% | — | |
| $0.65 | $43.21M | -0.09 | -8.58% | -28.51% | -242.96% | — | |
| $3.15 | $131.17M | -926.47 | 10.37% | 52.16% | — | — |
Compare NCNA vs Peers
NuCana plc (NCNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NCNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NCNA Frequently Asked Questions
NuCana plc (NCNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NCNA profitable?
NuCana plc (NCNA) reported a net loss of $30.8M for fiscal year 2025.
Dividend & Returns
What is NCNA's return on equity?
NuCana plc (NCNA) has a return on equity (ROE) of -193.9%. Negative ROE indicates the company is unprofitable.
What is NuCana plc's free cash flow?
NuCana plc (NCNA) had negative free cash flow of $4.2M in fiscal year 2025, likely due to heavy capital investments.